Dimier I H, Bout D T
Laborataire d'Immunologie Parasitaire, Université François Rabelais des Sciences Pharmaceutiques, Tours, France.
Immunol Cell Biol. 1997 Oct;75(5):511-4. doi: 10.1038/icb.1997.80.
Toxoplasma gondii is an obligate intracellular parasite which is responsible for severe disease after congenital infection and in immunocompromised patients, for which there is no effective therapy. In acquired toxoplasmosis, T. gondii first invade enterocytes and are disseminated throughout the body. Treatment of the adherent human intestinal cell line CaCO2 with recombinant human IFN-gamma inhibited the replication of T. gondii. Growth of the parasite was measured in vitro by [3H]-uracil incorporation assays 18 h after infection. This assay showed that when cells were pretreated with IFN-gamma concentrations ranging from 2.5 to 5000 U/ml, a high degree of inhibition of T. gondii replication could be observed, with the effect being dose dependent. This could be of relevance as a first line of defence against human Toxoplasma infection. Inhibition is due to a different mechanism from that existing in mouse macrophages and human fibroblasts: L-arginine-dependent production of reactive nitrogen intermediates, reactive oxygen intermediates synthesis or production of indoleamine 2.3 dioxygenase were not responsible for inhibition of T. gondii proliferation.
刚地弓形虫是一种专性细胞内寄生虫,在先天性感染后以及免疫功能低下的患者中会引发严重疾病,目前尚无有效的治疗方法。在获得性弓形虫病中,刚地弓形虫首先侵入肠上皮细胞并播散至全身。用重组人干扰素-γ处理贴壁的人肠细胞系CaCO2可抑制刚地弓形虫的复制。感染18小时后,通过[3H]-尿嘧啶掺入试验在体外测量寄生虫的生长。该试验表明,当细胞用浓度范围为2.5至5000 U/ml的干扰素-γ预处理时,可观察到对刚地弓形虫复制的高度抑制,且该效应呈剂量依赖性。这可能作为抵御人类弓形虫感染的第一道防线具有重要意义。抑制作用的机制与小鼠巨噬细胞和人成纤维细胞中的机制不同:依赖L-精氨酸产生的活性氮中间体、活性氧中间体的合成或吲哚胺2,3-双加氧酶的产生均不负责抑制刚地弓形虫的增殖。